Neurogenic Shock After SCI - Vasopressors

Key Points

• Neurogenic shock is distributive shock from sympathetic interruption; spinal shock is loss of neurologic reflexes and is a different entity.
• Never attribute hypotension in a trauma patient to neurogenic shock until hemorrhage and other life-threatening causes have been actively evaluated.
• Cervical and high thoracic injuries carry the greatest risk because they disrupt sympathetic outflow and may also impair respiration.
• Relative bradycardia supports the diagnosis but is not required, and tachycardia can occur with pain, bleeding, hypoxia, or medications.
• Use fluids to correct true volume deficit, then rely on vasopressors rather than repeated unstructured crystalloid loading for persistent vasoplegia.
• Norepinephrine is commonly used, but current SCI guidance does not require one specific vasopressor.
• Current SCI perfusion guidance suggests MAP at least 75 to 80 mm Hg, avoiding active augmentation above 90 to 95 mm Hg, generally for 3 to 7 days.
• Treat symptomatic bradycardia, respiratory failure, hypoxemia, and the underlying spinal compression or instability concurrently.

Algorithm

1. Reassess airway, breathing, circulation, and spinal precautions in any hypotensive patient with SCI.
2. Look immediately for hemorrhage, tension pneumothorax, tamponade, medication effect, and other competing causes of shock.
3. Give blood products for hemorrhagic shock and a cautious crystalloid challenge only when volume deficit remains plausible.
4. If vasodilatory hypotension persists after adequate preload, start a titratable vasopressor, commonly norepinephrine.
5. Target an individualized MAP consistent with current SCI perfusion guidance and the patient's comorbidities.
6. Treat clinically significant bradycardia with oxygenation, removal of triggers, atropine when appropriate, and escalation to epinephrine or pacing if unstable.
7. Monitor ECG, urine output, lactate or perfusion markers, respiratory status, and serial neurologic examination in an ICU setting.
8. Coordinate definitive spinal decompression and stabilization with the spine team.

Clinical Synopsis & Reasoning

Neurogenic shock is a hemodynamic complication of spinal cord injury caused by interruption of sympathetic pathways, most often with cervical or upper thoracic lesions. Loss of vascular tone causes reduced systemic vascular resistance and venous pooling, while unopposed vagal influence may produce bradycardia. The classic combination is hypotension with relative bradycardia and warm peripheral vasodilation, but real patients do not always display the textbook pattern. Trauma patients can simultaneously have hemorrhage, myocardial injury, tension pneumothorax, medication effects, or sepsis. Therefore neurogenic shock is not a diagnosis that should be made solely because a patient with spinal trauma is hypotensive and bradycardic.

The distinction from spinal shock is essential. Spinal shock refers to transient loss or depression of reflex activity below the level of injury and is a neurologic phenomenon, whereas neurogenic shock is circulatory failure. A patient may have either, both, or neither. The hemodynamic problem can worsen secondary spinal cord ischemia, so rapid recognition matters after bleeding and other immediately reversible causes have been addressed. Bedside assessment should include serial blood pressure and heart rate, perfusion, temperature, neurologic level, lung examination, FAST or other hemorrhage evaluation, ECG, and targeted ultrasound when useful.

Current 2024 AO Spine/Praxis guidance for acute traumatic SCI suggests maintaining MAP at least 75 to 80 mm Hg and not actively augmenting beyond 90 to 95 mm Hg for approximately 3 to 7 days. This recommendation is based on very low-quality evidence and applies to spinal cord perfusion broadly, not specifically to neurogenic shock. It provides a reasonable framework after immediate shock resuscitation, but blood pressure goals should be individualized to bleeding risk, cardiac reserve, age, and neurologic injury.

Treatment Strategy & Disposition

Start with standard trauma resuscitation. Secure the airway when respiratory mechanics are inadequate, give oxygen for hypoxemia, and control hemorrhage. Small, reassessed fluid boluses are appropriate when intravascular depletion is possible, but large-volume crystalloid loading is not a substitute for vasopressor therapy in vasoplegia and can produce pulmonary edema. Once major blood loss is excluded or corrected, a vasopressor is usually required to restore vascular tone and achieve an appropriate MAP.

Norepinephrine is commonly favored because it provides potent alpha-mediated vasoconstriction with some beta-1 activity and generally causes less tachycardia than dopamine. The 2024 SCI hemodynamic guideline does not mandate a particular vasopressor, so selection should reflect the patient's heart rate, ventricular function, vascular disease, access, and local critical-care practice. Phenylephrine can raise vascular tone but may worsen reflex bradycardia and reduce cardiac output in susceptible patients. Dopamine has historically been used but is associated with more arrhythmias in many critically ill populations. Epinephrine can support severe bradycardic shock when additional chronotropy and inotropy are needed.

Treat clinically significant bradycardia according to symptoms and perfusion rather than heart rate alone. Atropine may help vagally mediated bradycardia, particularly during suctioning or airway manipulation. Persistent unstable bradycardia may require epinephrine infusion or temporary pacing. Prevent triggers such as hypoxemia and excessive vagal stimulation. ICU monitoring is appropriate for significant neurogenic shock because blood pressure, rhythm, respiratory status, and neurologic examination can change rapidly. Definitive management of the spinal injury, including decompression and stabilization when indicated, proceeds in parallel.

Epidemiology / Risk Factors

• Neurogenic shock occurs predominantly in cervical and upper thoracic spinal cord injuries and is more likely with severe neurologic deficits.
• The reported incidence varies because definitions of hypotension, bradycardia, and injury severity differ across studies.
• Older adults with cervical injury may have limited cardiac reserve and medication-related bradycardia that complicate recognition and vasopressor selection.
• Concurrent hemorrhagic and neurogenic shock can coexist, particularly after high-energy trauma.

Investigations

Vasopressor Snapshot

Pharmacology

Prognosis / Complications

• Outcome is driven primarily by the severity and level of spinal cord injury rather than by the transient shock syndrome alone.
• Avoidance of sustained hypotension is associated with better neurologic recovery, although the optimal blood-pressure target remains uncertain.
• Bradyarrhythmias are often most prominent early after high cervical injury and may improve as autonomic function evolves.
• Complications of prolonged vasopressor therapy include arrhythmia, ischemia, line infection, and fluid imbalance, requiring continuous reassessment.

Patient Education / Counseling

• Explain that the low blood pressure is caused by loss of normal sympathetic vascular control after the cord injury, but bleeding must still be ruled out.
• Describe vasopressors as temporary medicines used to maintain blood flow to vital organs and the injured spinal cord while the acute phase stabilizes.
• Prepare families for ICU monitoring and the possibility of bradycardia, respiratory support, and repeated neurologic examinations.
• Clarify that normalization of blood pressure does not by itself predict neurologic recovery, which depends mainly on the underlying cord injury.
• Discuss that blood-pressure targets are based on limited evidence and are adjusted to the individual patient rather than treated as an absolute number.

Notes

The key diagnostic error in neurogenic shock is premature closure. A patient with a high spinal lesion can be vasodilated and bradycardic while also bleeding into the chest, abdomen, pelvis, or retroperitoneum. Trauma resuscitation and hemorrhage control therefore remain the first framework. The neurogenic component becomes clearer when hypotension persists despite adequate volume and bleeding control, particularly with a compatible neurologic level.

Modern SCI guidance also makes the uncertainty around perfusion targets explicit. The suggested MAP range of 75 to 80 mm Hg as a lower limit and 90 to 95 mm Hg as an upper active-augmentation boundary for 3 to 7 days is not supported by high-quality randomized evidence. It should improve consistency without becoming an excuse for excessive vasopressor exposure in a patient whose cardiac or vascular risk makes aggressive augmentation harmful.

References

1. AO Spine/Praxis Acute Spinal Cord Injury Guidelines, 2024 — Link
2. Clinical Practice Guideline on Hemodynamic Management of Acute SCI, 2024 — Link